In addition, this study found that the sensitivity, characteristic, accuracy, established predicted worth, and destructive predicted worth of preoperative NMP22 combined with CSTB in assessing bladder carcinoma recurrence after surgery were greater than those of preoperative NMP22 and CSTB alone, and the discrepancies were obvious. The gene discussed is NUMA1; the disease is urinary bladder carcinoma.